| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1200/JCO.2006.10.0677 |
| P698 | PubMed publication ID | 17538177 |
| P2093 | author name string | Robert L Fine | |
| Elizabeth R Gerstner | |||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | blood–brain barrier | Q221694 |
| brain tumor | Q233309 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 2306-2312 | |
| P577 | publication date | 2007-06-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm | |
| P478 | volume | 25 |
| Q41820394 | Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib |
| Q28710150 | Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions |
| Q34633703 | Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy |
| Q48632565 | Attributes of brain metastases from breast and lung cancer |
| Q57176317 | Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine |
| Q36284456 | Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial |
| Q48444978 | Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas |
| Q38259683 | Bone marrow-derived stem cell therapy for metastatic brain cancers |
| Q28078998 | Breast cancer brain metastases: biology and new clinical perspectives |
| Q35586669 | Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis |
| Q37573461 | Cancer and the metastatic substrate |
| Q35034764 | Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens |
| Q39331752 | Challenges in the delivery of therapies to melanoma brain metastases |
| Q38792519 | Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases |
| Q91410839 | Challenges to curing primary brain tumours |
| Q36721489 | Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer |
| Q24194415 | Chemotherapy for newly diagnosed inoperable brain metastases from non-small cell lung cancer |
| Q94401116 | Chemotherapy for newly diagnosed inoperable brain metastases from non‐small cell lung cancer |
| Q38096437 | Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. |
| Q46099780 | Chemotherapy-related posterior reversible leukoencephalopathy syndrome |
| Q38265614 | Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma |
| Q35146078 | Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. |
| Q44156403 | Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children |
| Q38691508 | Crossing the barrier: treatment of brain tumors using nanochain particles |
| Q36186315 | DNA topoisomerase I drugs and radiotherapy for lung cancer |
| Q27851801 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. |
| Q33794890 | Determinants of survival in patients with brain metastases from cutaneous melanoma |
| Q38759920 | Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. |
| Q47573654 | Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? |
| Q37362486 | Drug interactions at the blood-brain barrier: fact or fantasy? |
| Q34581741 | Early gastric cancer with suspected brain metastasis arising eight years after curative resection: a case report |
| Q39637384 | Effect of chemotherapy on survival after whole brain radiation therapy for brain metastases: a single-center retrospective analysis |
| Q37091154 | Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells |
| Q92874415 | Effects of Radiation Therapy on Neural Stem Cells |
| Q33620317 | Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases |
| Q38616077 | Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer |
| Q89408783 | Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier |
| Q46944135 | Eligibility of patients with brain metastases for phase I trials: time for a rethink? |
| Q38953017 | Embracing rejection: Immunologic trends in brain metastasis |
| Q88497994 | Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies |
| Q35075446 | Emerging strategies for treating brain metastases from breast cancer |
| Q37157248 | Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma |
| Q37968607 | Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment |
| Q34673086 | Fluorescent affibody peptide penetration in glioma margin is superior to full antibody |
| Q34565460 | Fluoxetine modulates breast cancer metastasis to the brain in a murine model |
| Q36851190 | Gliadel for brain metastasis. |
| Q34393640 | Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer |
| Q28540667 | In silico prediction of inhibition of promiscuous breast cancer resistance protein (BCRP/ABCG2) |
| Q37747100 | Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden |
| Q64057768 | Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis |
| Q59329795 | Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma |
| Q42593884 | Intercellular transfer of small RNAs from astrocytes to lung tumor cells induces resistance to chemotherapy |
| Q44647936 | Intrathecal application of donor lymphocytes in leukemic meningeosis after allogeneic stem cell transplantation |
| Q36371783 | Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. |
| Q34016491 | Lapatinib for the treatment of breast cancer in the People's Republic of China |
| Q46423087 | Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma |
| Q52087016 | Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options. |
| Q33989239 | MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas |
| Q57181658 | Magnetic targeting of paclitaxel-loaded poly(lactic--glycolic acid)-based nanoparticles for the treatment of glioblastoma |
| Q37812446 | Medical Management of Brain Metastases |
| Q38766796 | Melanoma Brain Metastases: Current Areas of Investigation and Future Directions |
| Q38807942 | Melanoma central nervous system metastases: current approaches, challenges, and opportunities |
| Q37738771 | Modern multidisciplinary management of brain metastases |
| Q37080236 | Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy |
| Q37819809 | Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier |
| Q37579928 | Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases |
| Q37303869 | New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer |
| Q35734471 | Novel treatment strategies for brain tumors and metastases |
| Q47944360 | Obstacles to Brain Tumor Therapy: Key ABC Transporters |
| Q38067340 | Optimal management of brain metastases from breast cancer. Issues and considerations |
| Q36888327 | Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells |
| Q39690634 | Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation |
| Q34708283 | Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. |
| Q98476068 | Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment |
| Q35627248 | Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report |
| Q48401767 | Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases |
| Q45046519 | Quantitative Fluorescence Microscopy Measures Vascular Pore Size in Primary and Metastatic Brain Tumors |
| Q48105538 | Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach |
| Q54962187 | Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. |
| Q42214301 | Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier |
| Q35071355 | Regression of brain metastases from breast cancer with eribulin: a case report |
| Q37084982 | Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan |
| Q38101607 | Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS. |
| Q38010057 | Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases |
| Q36898626 | Safety and efficacy of carmustine (BCNU) wafers for metastatic brain tumors. |
| Q60045957 | Safety evaluation of frequent application of microbubble-enhanced focused ultrasound blood-brain-barrier opening |
| Q30429246 | Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer |
| Q61809370 | Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report |
| Q33507517 | Small vessel ischemic disease of the brain and brain metastases in lung cancer patients |
| Q80940181 | Survival in patients with brain metastases from breast cancer: the importance of HER-2 status |
| Q48234725 | Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. |
| Q41428337 | Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. |
| Q39652258 | Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions |
| Q39675468 | TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy. |
| Q38715328 | Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors |
| Q37231972 | Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases |
| Q47247953 | The biology and therapeutic management of melanoma brain metastases |
| Q38564085 | The future of targeted therapies for brain metastases |
| Q38259586 | The management of brain metastases in non-small cell lung cancer |
| Q38614374 | The role of astrocytes in the progression of brain cancer: complicating the picture of the tumor microenvironment. |
| Q33599111 | The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline |
| Q37586262 | The role of chemotherapy in the treatment of patients with brain metastases from solid tumors |
| Q47735641 | The role of nivolumab in melanoma |
| Q58023833 | Therapie von Hirnmetastasen und Meningeosis neoplastica |
| Q37809862 | Therapy and prophylaxis of brain metastases |
| Q37967507 | Treatment of brain metastases: chemotherapy |
| Q44534087 | Vemurafenib and radiation therapy in melanoma brain metastases |
| Q50942238 | Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study. |
| Q84010105 | [Treatment of advanced metastatic melanoma] |
Search more.